Vericel’s MACI Revenue Primed for Fourth Quarter Growth

By Mike Evers

Vericel’s MACI Revenue Primed for Fourth Quarter Growth
The company's MACI revenue grew +18.2% in 3Q20 while record numbers of new biopsies point toward a sequential step up in fourth quarter revenue.

Member-Only Content

SUBSCRIBE Login

Product Labels: Orthobiologic Soft Tissue Repair

Tags: Revenue Report